Aldagen Funding Round

9/13/2007

Venture Equity

$9,000,000

Series C

The proceeds raised in this financing will be used to advance the development of Aldagen'sthree clinical-stage products. ALD-101, a unique stem cell therapy derived from cord blood, isbeing tested in an on-going Phase I clinical study to access its safety and ability to improve thespeed and efficacy of cord blood transplantation in the pediatric setting. Aldagen's two otherclinical-stage products, ALD-201 and ALD-301, are potent populations of stem and progenitorcells isolated from a patient's bone marrow. ALD-201 is currently being tested in a Phase I/IIclinical study at the Texas Heart Institute as a therapy for advanced heart failure patients. ALD-301 is being tested in a multi-site ongoing Phase I/II clinical study, which is the first clinical trialinvolving a novel stem cell therapy for critical limb ischemia patients in the United States.

Acquired or Merged

Biopharmaceutical

2810 Meridian Pkwy. 148
Durham, NC 27713
USA

Aldagen is a clinical-stage regenerative medicine company developingand commercializing products to treat vascular and degenerative diseases.The company's proprietary products can identify and isolate potent, highlyeffective adult stem and progenitor cells which can be quickly administeredto regenerate or repair tissue.